A phase I trial of perillyl alcohol in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 51, Issue 6, 2003, Pages 493-498

  Azzoli, Christopher G ^a   Miller, Vincent A ^a   Ng, Kenneth K ^a   Krug, Lee M ^a   Spriggs, David R ^a   Tong, William P ^a   Riedel, Elyn R ^a   Kris, Mark G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

G proteins; Isoprenylation; Limonene; Monoterpenes; p21 ras; Perillyl alcohol

Indexed keywords

DRUG METABOLITE; GUANINE NUCLEOTIDE BINDING PROTEIN; METOCLOPRAMIDE; ONDANSETRON; PERILLIC ACID; PERILLYL ALCOHOL; PROCHLORPERAZINE; TERPENE DERIVATIVE;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BELCHING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; EARLY SATIETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ISOPRENYLATION; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PLANT PRODUCT; PRIORITY JOURNAL; PROTO ONCOGENE; PROTO ONCOGENE P21 RAS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SOLID TUMOR; VOMITING;

EID: 0038051358     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0599-7     Document Type: Article

References (23)

1. Ariazi EA, Satomi Y, Ellis MJ, Haag JD, Shi W, Sattler CA, Gould MN (1999) Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59:1917
2. Barthelman M, Chen W, Gensler HL, Huang C, Dong Z, Bowden GT (1998) Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 58:711
3. Boon PJ, van der Boon D, Mulder GJ (2000) Cytotoxicity and biotransformation of the anticancer drug perillyl alcohol in PC12 cells and in the rat. Toxicol Appl Pharmacol 167:55
4. Crowell PL, Siar Ayoubi A, Burke YD (1996) Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer. Adv Exp Med Biol 401:131
5. Elegbede JA, Elson CE, Tanner MA, Qureshi A, Gould MN (1986) Regression of rat mammary tumors following dietary d-limonene. J Natl Cancer Inst 76:323
6. Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MN (1995) The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett 91:169
7. Haag JD, Gould MN (1994) Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34:477
8. Haag JD, Lindstrom MJ, Gould MN (1992) Limonene induced regression of mammary carcinomas. Cancer Res 52:4021
9. Hohl RJ, Lewis K (1995) Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270:17508
10. Homburger F, Treger A, Boger E (1971) Inhibition of murine subcutaneous and intravenous benso(rst)pentaphene carcinogenesis by sweet orange oils and d-limonene. Oncology 25:1
11. Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halberr T, Qian M, Gallo JM (2000) Phase I pharmacokinetic trial of perillyl alcohol (NSC641066) in patients with refractory solid malignancies. Clin Cancer Res 6:3071
12. Jirtle RL, Haag JD, Ariazi EA, Gould MN (1993) Increase mannose 6-phosphate/insulin-like growth factor II receptor and transforming growth factor beta-1 levels during monoterpene-induced regression of mammary tumors. Cancer Res 53:3849
13. Karlson J, Borg-Karlson AK, Unelius R, Shoshan MC, Wilking N, Ringborg U, Linder S (1996) Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a ras-independent mechanism of action. Anticancer Drugs 7:422
14. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
15. Ren Z, Elson CE, Gould MN (1997) Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol 54:113
16. Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH (1998) Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4:1159
17. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH (2000) Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6:390
18. Sahin MB, Perman SM, Jenkins G, Clark SS (1999) Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia 13:1581
19. Satomi Y, Miyamoto S, Gould MN (1999) Induction of AP-1 activity by perillyl alcohol in breast cancer cells. Carcinogenesis 20:1957
20. Sherman EJ, Pfister DG, Rubin D, Schwartz GK, Miller VA, Venkatraman ES, Radzyner M, Ruchlin HI, Spriggs D (2000) Using patients as their own controls to evaluate the cost of phase I trials (abstract). Proc Am Soc Clin Oncol 19
21. Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL (1998) Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res 18:823
22. Vigushin DM, Poon GK, Boddy A, Jarman M, Coombes RC (1998) Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer. Cancer Chemother Pharmacol 42:111
23. Zhang Z, Chen H, Chan KK, Budd T, Ganapathi R (1999) Gas chromatographic-mass spectrometric analysis of perillyl alcohol and metabolites in plasma. J Chromatogr B Biomed Sci Appl 728:85